Trial · NCT03456700
Adverse events44
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 44
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (Auranofin, Sirolimus) | 16 | 21 | 26 |
| other | Abdominal pain | Gastrointestinal disorders | Treatment (Auranofin, Sirolimus) | 1 | 21 | 1 |
| other | Diarrhea | Gastrointestinal disorders | Treatment (Auranofin, Sirolimus) | 17 | 21 | 32 |
| other | Mucositis oral | Gastrointestinal disorders | Treatment (Auranofin, Sirolimus) | 12 | 21 | 20 |
| other | Nausea | Gastrointestinal disorders | Treatment (Auranofin, Sirolimus) | 11 | 21 | 17 |
| other | Vomiting | Gastrointestinal disorders | Treatment (Auranofin, Sirolimus) | 9 | 21 | 12 |
| other | Edema limbs | General disorders | Treatment (Auranofin, Sirolimus) | 3 | 21 | 5 |
| other | Fatigue | General disorders | Treatment (Auranofin, Sirolimus) | 19 | 21 | 40 |
| other | Alkaline phosphatase increased | Investigations | Treatment (Auranofin, Sirolimus) | 2 | 21 | 3 |
| other | Cholesterol high | Investigations | Treatment (Auranofin, Sirolimus) | 1 | 21 | 1 |
| other | Creatinine increased | Investigations | Treatment (Auranofin, Sirolimus) | 3 | 21 | 3 |
| other | Lymphocyte count decreased | Investigations | Treatment (Auranofin, Sirolimus) | 7 | 21 | 12 |
| other | Neutrophil count decreased | Investigations | Treatment (Auranofin, Sirolimus) | 2 | 21 | 2 |
| other | Platelet count decreased | Investigations | Treatment (Auranofin, Sirolimus) | 6 | 21 | 12 |
| other | White blood cell decreased | Investigations | Treatment (Auranofin, Sirolimus) | 5 | 21 | 5 |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (Auranofin, Sirolimus) | 6 | 21 | 6 |
| other | Hyperglycemia | Metabolism and nutrition disorders | Treatment (Auranofin, Sirolimus) | 1 | 21 | 1 |
| other | Hypertriglyceridemia | Metabolism and nutrition disorders | Treatment (Auranofin, Sirolimus) | 2 | 21 | 2 |
| other | Arthralgia | Musculoskeletal and connective tissue disorders | Treatment (Auranofin, Sirolimus) | 9 | 21 | 15 |
| other | Back pain | Musculoskeletal and connective tissue disorders | Treatment (Auranofin, Sirolimus) | 1 | 21 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03456700/events